Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same author

Untargeted metabolomics and lipidomics to study autophagy induction in mouse embryonic fibroblasts.

Analytical and bioanalytical chemistry·2025
Same author

Structure-Property Investigation of New "KetoFAPI" Inhibitors of Fibroblast Activation Protein (FAP): Discovery of Highly Potent, Selective Compounds with Prolonged Residence Times and Promising Radiotheranostic Potential.

Journal of medicinal chemistry·2025
Same author

Role of FAPI PET/CT in cancer of unknown primary (CUP): A systematic review.

European journal of radiology·2025
Same author

Divergent prognostic utility of metabolic risk scores in large B-cell lymphoma subtypes: a real-world analysis.

European journal of nuclear medicine and molecular imaging·2025
Same author

Comparison of inter- and intraobserver agreement between [<sup>18</sup>F]AlF-NOTA-octreotide and [<sup>68</sup>Ga]Ga-DOTA-SSA PET/CT.

EJNMMI reports·2025

Related Experiment Video

Updated: Jul 16, 2026

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
07:45

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice

Published on: October 25, 2024

PET and PET/CT for response evaluation in lymphoma: current practice and developments.

Lieselot Brepoels1, Sigrid Stroobants, Gregor Verhoef

  • 1Department of Nuclear Medicine, University Hospital Gasthuisberg, Leuven, Belgium. lieselot.brepoels@uz.kuleuven.ac.be

Leukemia & Lymphoma
|February 28, 2007
PubMed
Summary

FDG-PET scans accurately distinguish viable lymphoma from fibrosis in residual masses after treatment. This imaging technique aids in assessing treatment response for Hodgkin

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Related Experiment Videos

Last Updated: Jul 16, 2026

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice
07:45

Preclinical Positron Emission Tomography with Body Conforming Animal Molds for Cloud-Based Automated Image Analysis in Mice

Published on: October 25, 2024

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Area of Science:

  • Nuclear Medicine
  • Oncology
  • Radiology

Background:

  • Residual masses are common after lymphoma treatment, but differentiating active tumor from fibrosis is challenging.
  • Conventional imaging lacks the specificity to distinguish viable tumor from scar tissue.
  • Accurate response assessment is crucial for guiding further treatment decisions in lymphoma patients.

Purpose of the Study:

  • To review the value of 2-[18F]fluoro-2-deoxy-d-glucose (FDG) Positron Emission Tomography (PET) for assessing treatment response in lymphoma.
  • To highlight FDG-PET's ability to differentiate active tumor from fibrosis in residual masses.
  • To discuss the role of FDG-PET in staging, response assessment, and prognosis in Hodgkin's disease (HD) and non-Hodgkin's lymphoma (NHL).

Main Methods:

  • Review of literature focusing on the application of FDG-PET in lymphoma response assessment.
  • Evaluation of FDG-PET's diagnostic performance compared to conventional radiological techniques.
  • Analysis of FDG-PET's utility in distinguishing viable tumor from post-treatment fibrosis.

Main Results:

  • FDG-PET can effectively differentiate between metabolically active tumor and inactive fibrotic tissue in residual masses.
  • This capability allows for more accurate assessment of treatment response than conventional imaging.
  • FDG-PET has demonstrated utility as an initial staging tool and prognostic marker.

Conclusions:

  • FDG-PET is a valuable tool for accurate response assessment in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
  • Its ability to distinguish viable tumor from fibrosis improves treatment stratification and management.
  • The review emphasizes the significant role of FDG-PET in the clinical management of lymphoma.